Henlius’ Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 clinical trial, significantly reducing recurrence risk and improving cure rates. No immunotherapy has been approved globally for gastric cancer perioperative treatment...
Clarity Eye Centre Brings SILK™ Laser Eye Technology to Hong Kong
HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients in Hong Kong. The clinic is the first in the city to widely offer the ELITA™ Femtosecond Laser, the advanced system that powers SILK™ (Smooth Incision Lenticule...
Gong Yingying: The Next Era of AI Healthcare Requires Trust, Real-World Scenarios, and Universal Accessibility
KUALA LUMPUR, Malaysia, Nov. 20, 2025 /PRNewswire/ -- At the 2025 Fortune Innovation Forum in Kuala Lumpur, global industry leaders and innovators gathered to explore the technologies transforming healthcare. Speaking at the featured roundtable "AI vs. MD," Ms. Gong Yingying, Founder and Chairwoman of Yidu Tech, shared her perspective on the responsible development of AI in healthcare. She was...
Smartee Deepens Its Strategy for Central Asia and Russia in 2025
SHANGHAI, Nov. 20, 2025 /PRNewswire/ -- Smartee Denti-Technology is reinforcing its international footprint with a focused strategy in Central Asia and Russia for 2025, cementing its position as a global leader in clear aligner and digital orthodontic technologies. This year, Smartee showcased its innovative orthodontic solutions at major regional exhibitions, including Dental Salon Moscow (April), Kazdent Expo Almaty and IDECA...
Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide
Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed Adoption of Remplir™ among Australian urologists is accelerating, with ~100 surgeries conducted by surgeons nationwide. This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company. Despite...
Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that at the R&D Day taking place today, it will...
Dr James Liang Launches HK$500 Million “Genovation Foundation” to Address Low Fertility
HONG KONG, Nov. 20, 2025 /PRNewswire/ -- On World Children's Day, Dr James Liang, Co-founder of Trip.com Group, announced the establishment of the Genovation Foundation Limited in Hong Kong. Established in his personal capacity, the foundation pledges HK$500 million over five years to address declining fertility through three key avenues: economic subsidies, cultural advocacy, and policy research. The name Genovation...
WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry
WuXi AppTec sets new benchmarks in strategic execution and technological advancement, further strengthening its ability to support innovators worldwide as they deliver breakthrough medicines for patients. SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that WuXi AppTec has received the 2025 Global Company of the Year Recognition in the contract research, development, and manufacturing organization...
USANA Named No. 1 Dietary Supplements Brand in the Philippines for the 7th Consecutive Year
Euromonitor Recognizes USANA Philippines as the Market Leader from 2019 to 2025 MANILA, Philippines, Nov. 20, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in health and wellness, has once again been recognized as the No. 1 dietary supplements brand in the Philippines* by Euromonitor International—marking an unprecedented seven consecutive years...
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab) PET/CT would have undergone a change in clinical management, when compared with baseline standard of care...
